Wedbush Downgrades Raptor Pharmaceuticals (RPTP) to Neutral
Tweet
Share
E-mailGet Alerts RPTP Hot Sheet
Price: $9.00 --0%
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush downgraded Raptor Pharmaceuticals (NASDAQ: RPTP) from Outperform to Neutral with a price target of $7.00 (from $10.00).
Analyst Gregory R. Wade said "We expect a decision from the FDA’s Office of Orphan Drugs on PROCYSBI’s potential orphan drug exclusivity in the next 6-8 weeks to be the next catalyst for RPTP shares. PROCYSBI has orphan drug designation, but a decision on orphan drug exclusivity, which would ensure at least 7 year of exclusivity, has not yet been rendered. PROCYSBI’s patents expire in 2027 . . .We arrive at our $7 price target by applying a 15x multiple to fully taxed (40%) 2016 EPS discounted annually 20%."
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $6.68 yesterday.
Analyst Gregory R. Wade said "We expect a decision from the FDA’s Office of Orphan Drugs on PROCYSBI’s potential orphan drug exclusivity in the next 6-8 weeks to be the next catalyst for RPTP shares. PROCYSBI has orphan drug designation, but a decision on orphan drug exclusivity, which would ensure at least 7 year of exclusivity, has not yet been rendered. PROCYSBI’s patents expire in 2027 . . .We arrive at our $7 price target by applying a 15x multiple to fully taxed (40%) 2016 EPS discounted annually 20%."
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $6.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
- Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
